[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_95":96},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","trqmkivdha66wxzbpmgcfl7bv","revision",2,"title","AngioDynamics 任命 Eric Honroth 为新任首席执行官","originalTitle","ANGIODYNAMICS INC (0001275187) (Filer)","summary","AngioDynamics 任命 Eric Honroth 为新任首席执行官，自 2026 年 11 月 2 日起生效。Honroth 将获得 73.5 万美元年薪及最高 95% 的年度奖金。他此前曾任职于 Getinge AB、Abbott Vascular 等公司。","reason","source",{"_11":85,"_86":87,"_88":89,"_90":57,"_91":92,"_93":94},"links",{"_82":83,"_63":84},"publishedAt","2026-10-08T11:16:17.000Z","discoveredAt","2026-10-08T11:40:35.215Z","timelineAt","category","ai-products","tags",[81],"stockSymbols",[80],"score",45,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fjCfBwasatmc",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","67dec19c-e6d3-4f39-9d7e-eed4c93dc527","AngioDynamics 任命新任首席执行官",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 2, 2026

AngioDynamics, Inc.
\n

(Exact Name of Registrant as Specified in Charter)

\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n

\n Delaware \n \n	\n 000-50761 \n \n	\n 11-3146460 \n \n

\n (State or Other Jurisdiction of Incorporation) \n	\n (Commission File Number) \n	\n (IRS Employer Identification No.) \n

\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n

\n 14 Plaza Drive,\n Latham, New York \n		\n 12110 \n \n

\n (Address of Principal Executive Offices) \n		\n (Zip Code) \n

(518) 795-1400

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to\n simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

\n\n\n \n\n \n\n \n\n \n\n\n

☐ \n	\n Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) \n

\n\n\n \n\n \n\n \n\n \n\n\n

☐ \n	\n Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) \n

\n\n\n \n\n \n\n \n\n \n\n\n

☐ \n	\n Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) \n

\n\n\n \n\n \n\n \n\n \n\n\n

☐ \n	\n Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c)) \n

Securities registered pursuant to Section 12(b) of the Act:

\n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n

Title of each class

Trading Symbol(s)

Name of each exchange on which

registered

Common Stock, par value $0.01 per share
\n

ANGO
\n

NASDAQ Global Select Market
\n

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of\n the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised\n financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 – Entry into a Material Definitive Agreement.

On October 3, 2026, AngioDynamics, Inc. (“AngioDynamics” or the “Company”) entered into an employment agreement with Eric Honroth (the “Employment Agreement”), pursuant to\n which Mr. Honroth will serve as President and Chief Executive Officer of the Company. A description of the Employment Agreement is contained in Item 5.02 below, which is incorporated by reference into this Item 1.01. A copy of the Employment\n Agreement is attached to this Current Report on Form 8-K as Exhibit 10.1, and the terms of the Employment Agreement are incorporated herein by this reference.

Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain\n Officers.

CEO Appointment

As previously disclosed, James C. Clemmer has announced his intention to retire from his position as the President and Chief Executive Officer of\n the Company on the earlier of November 30, 2026 and appointment of a successor Chief Executive Officer. Mr. Clemmer has served as the Company’s President and Chief Executive Officer since April 2016.

On October 2, 2026, the Board of Directors of the Company (the “Board”)\n appointed Eric Honroth to serve as President and Chief Executive Officer of the Company, effective as of November 2, 2026 (the “Effective Date”) and concurrently with Mr.\n Clemmer’s retirement. Prior to his appointment as President and Chief Executive Officer, Mr. Honroth, age 55, most recently served as President Life Science at Getinge AB, a medical technology company, from 2018 to 2026. Previously, Mr. Honroth\n served in senior leadership roles at Abbott Vascular, Becton Dickinson, CareFusion, and Boston Scientific. Mr. Honroth is a graduate of Miami University, Farmer School of Business in Oxford, Ohio.

In addition, Mr. Honroth was appointed as a director on the Company’s Board as of the Effective Date, conditioned upon his commencement of service\n as President and Chief Executive Officer and concurrently with Mr. Clemmer’s retirement from his position as a member of the Board. Mr. Clemmer has served as a member of the Board since 2016 and his decision to retire was not the result of any\n disagreement between Mr. Clemmer and the Company on any matter relating to the Company’s operations, polices or practices.

Mr. Honroth does not have any family relationships with any of the Company’s directors or executive officers. There is no arrangement or\n understanding between Mr. Honroth and any other person pursuant to which Mr. Honroth was appointed to serve as the Company’s President and Chief Executive Officer or a member of the Board, and there are no transactions to which Mr. Honroth has a\n direct or indirect material interest requiring disclosure under Item 404(a) of Regulation S-K.

Honroth Employment Agreement

In connection with Mr. Honroth’s appointment as President and Chief Executive Officer, on October 3, 2026, the Company and Mr. Honroth entered into\n the Employment Agreement. Pursuant to the Employment Agreement, Mr. Honroth will serve as the Company’s President and Chief Executive Officer, commencing on the Effective Date, for an initial one-year term, which\n automatically renews for successive one-year periods unless either party notifies the other in writing at least sixty days prior to the anniversary of the Effective Date.

Mr. Honroth will receive a base salary of $735,000 per year (the “Base Salary”)\n\n\n\n and will be eligible for annual bonuses at a target level of 95% of the Base Salary (the “Target Annual Bonus”), with the annual bonus opportunity in the first calendar year\n prorated based on the Effective Date.

Mr. Honroth will also be eligible to receive annual long-term incentive awards under the Company’s 2020 Stock and Incentive Award Plan, as amended\n (the “Equity Plan”). All annual equity awards shall be determined by the Compensation Committee and the Board, in their sole and absolute discretion, and shall be subject to the\n terms of the Equity Plan and the applicable award agreements.

Under the terms of the Employment Agreement, and contingent upon the commencement of Mr. Honroth’s service as President and Chief Executive\n Officer, Mr. Honroth will receive the following grants, effective as of the Effective Date, (i) a long-term incentive award with a grant-date value equal to $1,487,116 (which is equal to 350% of the Base Salary prorated based on the Effective Date in\n relation to the Company’s fiscal year) and consisting of 50% restricted stock units and 50% performance share units, subject to the terms and conditions of the applicable award agreement, (ii) in order to replace compensation forfeited by Mr. Honroth\n from his prior employer, a one-time award of restricted stock units with a grant-date value equal to $450,000, which will vest in two equal installments on the first and second anniversaries of the Effective Date, subject to Mr. Honroth’s continued\n employment and (iii) a cash sign-on bonus of $350,000. If Mr. Honroth voluntarily resigns from employment without Good Reason (as defined in the Employment Agreement) or is terminated for Cause (as defined in the Employment Agreement) before the\n first anniversary of the Effective Date, Mr. Honroth shall repay the gross amount of the sign-on bonus to the Company within ninety days following the date of termination. No repayment shall be required if Mr. Honroth’s employment terminates due to\n death, Disability (as defined in the Employment Agreement), termination by the Company without Cause, or resignation by Mr. Honroth for Good Reason.

In addition, under the Employment Agreement, Mr. Honroth will receive (i) for up to 24 months following the Effective Date, a monthly commuting and\n temporary living allowance of $10,000, pro-rated for any partial month, to offset commuting and temporary living expenses incurred in connection with Mr. Honroth’s travel to and from and lodging in New York, (ii) an automobile allowance at an annual\n rate of $24,000 and (iii) reimbursement for reasonable travel and lodging costs incurred in connection with business travel during the period of employment. Mr. Honroth will also be eligible to participate in the employee benefit plans and programs\n generally available to senior executives of the Company.

Mr. Honroth’s employment may be terminated by either party at any time. If Mr. Honroth’s employment is terminated for any reason, Mr. Honroth\n shall be entitled to: (i) any accrued and unpaid Base Salary; (ii) payment for accrued and unused vacation time, if required by Company policy or applicable law; (iii) reimbursement for any approved business expenses incurred during the term of\n employment; and (iv) any rights surviving termination of employment under any employee benefit plan or program or compensation arrangement in which Mr. Honroth participates (collectively, the “Accrued Benefits”).

If the Company terminates Mr. Honroth’s employment without Cause or Mr. Honroth terminates his employment for Good Reason, Mr. Honroth shall be\n entitled to the following, in addition to the Accrued Benefits: